There is an ongoing debate on which biomarkers should be measured to predict a tumor’s response to immunotherapy, but researchers have demonstrated that markers such as the presence of mature Tertiary Lymphoid Structures [85] (mTLS), high PD-L1 expression [86], high TMB [87], and high MSI [88] are positively associated with immunotherapy responses. The gene discussed is CD274; the disease is neoplasm.